GlaxoSmithKline, Fiocruz To Develop New Medicines For Tropical Diseases

Posted AtEnglish.capital.gr

LONDON -(Dow Jones)- GlaxoSmithKline PLC (GSK.LN), and the Oswald Cruz Foundation or Fiocruz Friday announced a unique collaboration to research and develop new and innovative medicines to treat diseases which disproportionately affect people living in the world's poorest countries.

MAIN FACTS:

-The agreement will initially be focused on Chagas and Leishmaniasis because of the experience of Fiocruz in these areas and the severe burden of unmet medical need for patients living with these diseases.

-This new collaborative framework, builds on a long-standing relationship between Fiocruz and GlaxoSmithKline, established in 1985, to manufacture vaccines for public health priorities in Brazil.

-These include polio, Haemophilus influenzae type b (Hib), measles, mumps, rubella, rotavirus and most recently pneumococcal disease.

-The relationship has also supported the development of research and manufacturing capabilities in Brazil through technology transfer and scientific collaboration.

Nov 15, 2010